Last reviewed · How we verify
CYPROHEPTADINE HYDROCHLORIDE
At a glance
| Generic name | CYPROHEPTADINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1961 |
Approved indications
Common side effects
- Sedation and sleepiness
- Dizziness
- Disturbed coordination
- Confusion
- Restlessness
- Excitation
- Nervousness
- Tremor
- Irritability
- Insomnia
- Paresthesias
- Neuritis
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- The Use of Cyproheptadine in Pediatric Feeding Disorders (PHASE4)
- Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (PHASE4)
- Loratadine for the Prevention of G-CSF-related Bone Pain (PHASE2)
- The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis (NA)
- Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers (NA)
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYPROHEPTADINE HYDROCHLORIDE CI brief — competitive landscape report
- CYPROHEPTADINE HYDROCHLORIDE updates RSS · CI watch RSS